Evidence map›Paper›PMID 32630478›Full record

ArticleCancers2020

Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer.

Bianca Grosser, Meike Kohlruss, Julia Slotta-Huspenina, Moritz Jesinghaus, Nicole Pfarr, Katja Steiger, Alexander Novotny, Matthias M Gaida, Thomas Schmidt, Alexander Hapfelmeier and 3 more

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Low microsatellite instability revisited: a review.Virchows Archiv : an international journal of pathology · 2026
    Review
  2. Article
  3. Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bianca GrosserInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.
Meike KohlrussInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.
Julia Slotta-HuspeninaInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.
Moritz JesinghausInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.
Nicole PfarrInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-5977-5375
Katja SteigerInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-7269-5433
Alexander NovotnyDepartment of Surgery, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-8029-5958
Matthias M GaidaInstitute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany.
Thomas SchmidtDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-7166-3675
Alexander HapfelmeierInstitute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0001-6765-6352
Katja OttDepartment of Surgery, Klinikum Rosenheim, 83022 Rosenheim, Germany.
Wilko WeichertInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.
Gisela KellerInstitute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany.

Funding

Deutsche Krebshilfe 70112177, 70112380
6 · The paper itself

Abstract

We investigated the prognostic and predictive impact of p53 expression for gastric cancer (GC) patients treated without or with preoperative chemotherapy (CTx) and its relationship with specific molecular GC subtypes. Specimens from 694 GC patients (562 surgical resection specimens without or after CTx, 132 biopsies before CTx) were analyzed by p53 immunohistochemistry. High (H) and low (L) microsatellite instability (MSI) and Epstein-Barr virus positivity were determined previously. Our results show that aberrant p53 expression was a negative prognostic factor in uni- and multivariable analysis in the resection specimens cohort (each

Indexed as

adenocarcinomagastricgastroesophageal junctionmicrosatellite instabilitymolecular subtypeneoadjuvant chemotherapyp53prognosis

Identifiers

PMID32630478
PMCPMC7352381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.